Search / Trial NCT06612047

Comparison of 5.0T and 3.0T Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer

Launched by ANHUI PROVINCIAL HOSPITAL · Sep 21, 2024

Trial Information

Current as of December 30, 2024

Not yet recruiting

Keywords

Prostate Cancer Prostate Biospy Biparametric Magnetic Resonance Prostate Imaging Reporting And Data System Diagnosis

ClinConnect Summary

The methods currently recommended by the guidelines for early diagnosis of prostate cancer mainly include rectal examination, serum prostate-specific antigen detection, transrectal prostate ultrasound, and multi-parameter magnetic resonance imaging. However, these methods lack sufficient specificity for the diagnosis of prostate cancer. Therefore, prostate biopsy is still the gold standard for the diagnosis of prostate cancer. mpMRI has good accuracy in detecting clinically significant prostate cancer, but mpMRI is difficult to identify lesions with a tumor diameter of less than 5 mm, and f...

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. The patient has at least one indication for prostate biopsy (Chinese expert consensus on prostate biopsy (2022 edition) );
  • 2. The primary prostate cancer has no other cancer history;
  • 3. The 3.0TbpMRI examination was completed, and the images were clear and accessible;
  • 4. The 5.0TbpMRI examination was further completed, and the images were clear and accessible;
  • 5. The patient fully understands the relevant content of the study and voluntarily signs the informed consent.
  • Exclusion Criteria:
  • 1. The patient has contraindications to MRI examination, such as metal plates and heart stents in the body;
  • 2. The patient does not have an indication for prostate biopsy or refuses biopsy;
  • 3. The patient has contraindications to prostate biopsy;
  • 4. 3.0T MRI considers that the patient has multiple lymph node or bone metastases;
  • 5. The patient has undergone other prostatic surgery in the past;
  • 6. The patient is unable to cooperate, has communication barriers, or refuses to sign the informed consent form.

Trial Officials

Jun Xiao, M.D.

Principal Investigator

The First Affiliated Hospital of USTC

About Anhui Provincial Hospital

Anhui Provincial Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital leverages its extensive expertise in various medical fields to enhance patient outcomes and contribute to the global body of medical knowledge. With a focus on translating research findings into practical applications, Anhui Provincial Hospital is dedicated to fostering collaboration among healthcare professionals and researchers, ensuring that cutting-edge treatments and interventions are accessible to the communities it serves.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0